These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26983335)

  • 1. [Risk and benefit of sulfonylureas--their role in view of new treatment options for type 2 diabetes].
    Rustenbeck I
    Med Monatsschr Pharm; 2016 Feb; 39(2):65-72; quiz 73-4. PubMed ID: 26983335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents.
    Colagiuri S; Matthews D; Leiter LA; Chan SP; Sesti G; Marre M
    Diabetes Res Clin Pract; 2018 Sep; 143():1-14. PubMed ID: 29802958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality risk among sulfonylureas: a systematic review and network meta-analysis.
    Simpson SH; Lee J; Choi S; Vandermeer B; Abdelmoneim AS; Featherstone TR
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):43-51. PubMed ID: 25466239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas.
    Sato R; Watanabe H; Genma R; Takeuchi M; Maekawa M; Nakamura H
    Pharmacogenomics; 2010 Dec; 11(12):1743-50. PubMed ID: 21142918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
    Bell DS
    Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Glimepiride--an oral antidiabetic agent].
    Becić F; Kapić E; Becić E
    Med Arh; 2003; 57(2):125-7. PubMed ID: 12822388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.
    Confederat L; Constantin S; Lupaşcu F; Pânzariu A; Hăncianu M; Profire L
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):579-84. PubMed ID: 26204670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
    Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is gliclazide a sulfonylurea with difference? A review in 2016.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating gliclazide for the treatment of type 2 diabetes mellitus.
    Tomlinson B; Li YH; Chan P
    Expert Opin Pharmacother; 2022 Dec; 23(17):1869-1877. PubMed ID: 36300277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of sulfonylureas in the treatment of type 2 diabetes.
    Tomlinson B; Patil NG; Fok M; Chan P; Lam CWK
    Expert Opin Pharmacother; 2022 Feb; 23(3):387-403. PubMed ID: 34758676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
    Rosenkranz B
    Horm Metab Res; 1996 Sep; 28(9):434-9. PubMed ID: 8911979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral hypoglycemic agents in type II diabetes mellitus.
    Lubbos H; Miller JL; Rose LI
    Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Glimepiride in daily practice].
    Jasik M
    Przegl Lek; 2003; 60(6):409-12. PubMed ID: 14974179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of glimepiride in the effective management of Type 2 diabetes.
    Davis SN
    J Diabetes Complications; 2004; 18(6):367-76. PubMed ID: 15531188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
    Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
    Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies.
    Azoulay L; Suissa S
    Diabetes Care; 2017 May; 40(5):706-714. PubMed ID: 28428321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral antidiabetic therapy].
    Schneider S; Pazdzierny G; Klein HH
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S264-7. PubMed ID: 17139584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pitfalls and precautions concerning the use of conventional oral antidiabetic drugs].
    Scheen AJ
    Rev Med Liege; 2002 May; 57(5):352-6. PubMed ID: 12143186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroglycopenic Seizures: Sulfonylureas, Sulfamethoxazole, or Both?
    Khan U; Seetharaman S; Merchant R
    Am J Med; 2017 Jan; 130(1):e29-e30. PubMed ID: 27593606
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.